European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer.

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Revolutionary drug Lepodisiran dramatically lowers Lp(a) cholesterol, a major heart attack risk factor. Learn about this ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Eli Lilly and Co. joined several other investors in a Series A round for a Boston biotech co-founded by the Longwood Fund that's developing a drug for a rare type of blood cancer.